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a signiﬁcant threat and a global problem when it comes to the
detection and treatment of infections [1]. Since their ﬁrst dis-
covery in 1996 in the United States, CPEs harbouring one of the
Ambler class A enzymes, the Klebsiella pneumoniae carbapene-
mases (KPC), have been detected in many geographic regions
[2]. They have disseminated rather rapidly, reaching endemic
proportions in countries such as Greece, Italy and Israel [3].
We document here for the ﬁrst time [4] detection of a KPC-
3-producing K. pneumoniae clinical isolate in Albania.
A 48-year-old man was transferred to the intensive care unit
of the University Hospital ‘Shefqet Ndroqi’ in Tirana, Albania,
on 25 March 2014 with the diagnosis of acute descending
necrotizing mediastinitis. Five days earlier, the patient was
admitted to the emergency department at University Hospital
Center of Tirana ‘Mother Theresa’ for cervical and corporal
trauma and then to the otolaryngology service of the same
hospital. The initial antibacterial treatment in the University
Hospital ‘Shefqet Ndroqi’ included piperacillin/tazobactam and
ciproﬂoxacin, a combination established as part of the empirical
treatment of serious infections in this hospital. Three days later,
he was taken to the operating room because his overall situa-
tion deteriorated. He underwent right posterolateral thora-
cotomy for debridement and drainage. On hospital day 7, the
therapy was switched to meropenem and moxiﬂoxacin.
A multidrug-resistant (MDR) Acinetobacter baumannii (sus-
ceptible only to gentamicin and colistin) was isolated from the
surgical wound swab on 2 April. Two weeks later, a microbi-
ology sample from the urinary catheter of the patient yielded
K. pneumoniae. The isolate was resistant to all tested antibiotics
except gentamicin by disc diffusion susceptibility testing.
The K. pneumoniae isolate was stored and later sent to the
University of Antwerp for further investigation. TheNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artiidentiﬁcation of the strain was conﬁrmed with matrix-assisted
laser desorption-ionization time-of-ﬂight mass spectrometry
(Bruker Daltonics). Antimicrobial susceptibility testing was
determined by using the Etest method (bioMérieux) (Tables 1
and 2). Results were interpreted according to European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines (http://www.eucast.org/clinical_breakpoints/).
The isolate was tested by PCR for the presence of extended-
spectrum β-lactamase and carbapenemase genes: blaCTX-M,
blaSHV, blaTEM, blaKPC, blaNDM, blaOXA-48, blaBIC, blaVIM, blaSIM,
blaIMP, blaSPM, blaGIM, blaAIM and blaDIM [5]. The strain was found
to be blaSHV and blaKPC positive. Subsequent sequencing
revealed the presence of genes encoding an SHV-11 extended-
spectrum β-lactamase and a KPC-3 carbapenemase, respec-
tively. Multilocus sequence typing identiﬁed sequence type (ST)
512 (allelic proﬁle: 54-3-1-1-1-1-79), a single locus variant
(c176a transversion in the gapA locus) of the pandemic clone
ST258 (allelic proﬁle: 3-3-1-1-1-1-79) [6,7].
Sporadic occurrences, hospital outbreaks and even more
signiﬁcant spread of KPC-producing Enterobacteriaceae to
many health care institutions or nursing homes have been re-
ported from many countries in Europe [2,7]. National experts
have recently reported sporadic occurrences of KPC in Albania
based on self-assessment, but these cases have not been
documented or published in peer-reviewed journals. To our
knowledge, this is the ﬁrst conﬁrmed infection with KPC-
producing Enterobacteriaceae in Albania.
KPC-producing Enterobacteriaceae have been a growing
threat in the Balkan region, particularly in Greece, during the past
several years [8,9]. Italy is also a hot spot for CPEs. In 2012, Pul-
crano et al. [7] reported theﬁrst outbreakofK. pneumoniae ST512
producing KPC-3 carbapenemase in southern Italy. Northern
Italy has not been spared either, with the multifocal diffusion of
KPC-3 detected in the same year [10]. The geographical location
of Albania, which neighboursGreece and Italy, may also result in a
predisposition to the appearance of CPEs in the country.
The patient had no history of recent travel to these two
countries, or of any relatives residing there who might haveNew Microbe and New Infect 2015; 4: 11–12
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TABLE 1. Antimicrobial susceptibility testing resultsa
Antibiotic
tested
Dose
(μg)
Klebsiella pneumoniae
(strain AL03)
Acinetobacter baumannii
(strain AL10)
Zone diameter (mm) Zone diameter (mm)
Ceftazidime 30 6 6
Cefotaxime 30 6 6
Cefoxitin 30 6 6
Cefepime 30 9 10
Imipenem 10 6 13
Meropenem 10 6 6
Gentamicin 10 18 18
Amikacin 30 11 9
Ciproﬂoxacin 5 6 6
aFollowing European Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines.
12 New Microbes and New Infections, Volume 4 Number C, March 2015 NMNIvisited him. No previous hospitalizations, apart from the one
preceding the admission in the intensive care unit, or intake of
antibiotics have been reported for this patient. During his
hospital stay, the patient’s clinical status complicated with a
gastro-oesophageal ﬁstula, and he underwent a feeding gastro-
stomy. The patient was discharged 2 months after admission in
an improved status.
Antimicrobial susceptibility testing of carbapenems in the
University Hospital ‘Shefqet Ndroqi’ started only in 2013. Until
the isolation of the strain in question, three other
K. pneumoniae isolates had been registered as resistant to car-
bapenems, but they had not been conﬁrmed by any genetic
testing or stored for further testing. Therefore, it is likely that
KPC-producing K. pneumoniae strains were already circulating
in the hospital before our detection. The total number of iso-
lated K. pneumoniae in the hospital for the period August 2013
to August 2014 was low, only 19, mainly as a result of the small
number of samples.
The nosocomial transmission of K. pneumoniae, which has
been frequently described, is a plausible explanation for the
occurrence of infection in this reported case, although no
outbreak investigations of KPC-producing Enterobacteriaceae
have been conducted among patients within the hospital.TABLE 2. Minimum inhibitory concentrations (MIC) of
antibiotics tested (K. pneumoniae strain AL03)a
Antibiotic tested MIC (mg/L)
Ceftazidime >32
Cefotaxime 32
Cefepime 64
Piperacillin/tazobactam >256
Imipenem >32
Meropenem >32
Gentamicin 4
Amikacin 64
Colistin 2
aFollowing European Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines.
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceFurther efforts are needed and are currently ongoing to assess
the actual spread of KPC-producing Enterobacteriaceae and
potentially other CPEs in Albania, and speciﬁcally at the Uni-
versity Hospital ‘Shefqet Ndroqi.’ These KPC-producing
K. pneumoniae ST512 could spread rapidly in Albania and are
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